In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations ...

More than 19,000 people infected with influenza, including over 900 hospitalizations and 44 deaths, were reported to DPHHS during the 2023 ... vaccines are available to protect against severe outcomes ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

Cassandra Archer, MD, FACP, FAAP, is director of community health services at the Cayuga County Health Department. For more ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

Executive Summary - Despite the demonstrated effectiveness of prenatal vaccines, uptake remains low. This puts mothers and babies ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

RESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...